All In Biotech

Free tool

FAERS Monitor: Motpoly Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216185 or its brand name (Motpoly Xr, Lacosamide). Reports on generic versions are filed under their own applications.

Reports

19,419

Serious

16,935

87% of reports

Hospitalization

7,397

Death reported

1,904

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure3,522
  • drug ineffective3,033
  • off label use2,359
  • status epilepticus811
  • dizziness741
  • drug interaction736
  • epilepsy720
  • fall716
  • somnolence701
  • generalised tonic-clonic seizure674
  • overdose652
  • multiple-drug resistance603
  • maternal exposure during pregnancy592
  • death587
  • fatigue578

Reports by year received

View as table
YearReports
20081
2009197
2010397
2011496
2012282
2013205
2014218
2015267
2016380
2017660
20181,320
20191,379
20201,326
20211,806
20221,896
20232,023
20242,509
20252,360
20261,697

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multiple-drug resistanceSignal603261.2239.2125,728
status epilepticusSignal81183.778.161,497
generalised tonic-clonic seizureSignal67445.942.628,406
seizureSignal3,52234.033.0110,054
epilepsySignal72026.124.316,969
maternal exposure during pregnancySignal5927.26.73,168
drug interactionSignal7365.04.72,389
somnolenceSignal7013.83.51,440
overdoseSignal6523.33.01,039
off label useSignal2,3592.92.83,104
drug ineffectiveSignal3,0332.52.42,893
fallSignal7162.32.2552
dizziness7411.61.5175
fatigue5780.80.728
death5870.70.757

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.